ChiralReach
Integrated Chromatography and Chemical Synthesis
ChiralReach is an integrated solution that unites preparative chiral chromatography with scalable asymmetric route development, ensuring both immediate delivery of enantiopure material and long‑term manufacturability under one coordinated programme.
- Overview
- ChiralReach workflow
- What you achieve with ChiralReach
- The ChiralReach solution
- What sets us apart
Chiral drug programmes face a dilemma: biology and tox studies need enantiopure material now, but scalable asymmetric synthesis takes time and working sequentially only makes things slower and riskier.
ChiralReach does both at once – a fully integrated chiral development programme that delivers enantiopure material rapidly for early-stage studies, while concurrently building a scalable asymmetric synthesis route.
The ChiralReach Solution
By combining chromatographic separation, asymmetric chemistry and rigorous analytical support within a single, unified timeline, ChiralReach eliminates the delays of sequential workflows. You achieve:
– Rapid supply of enantiopure material to keep early biology and tox studies on track
– Concurrent asymmetric route development, removing the need for sequential workflows
– Rigorous analytical integration across separation and synthesis workstreams
– A unified timeline from candidate selection through to IND-enabling studies
What Sets Us Apart
Our process chemistry team builds asymmetric routes that are robust, efficient, and phase-appropriate, ready for tech transfer to GMP manufacturing. Our capabilities include:
– Asymmetric synthesis
– Direct crystallisation
– Kinetic resolution
– Diastereomeric resolution
– Catalysis
This integrated capability ensures your enantiopure API can be delivered at scale, safely and reliably.
While chromatography supplies immediate material, automated HTE explores hundreds of reaction conditions in parallel to identify scalable, selective chemistry. Aligned with the DMTS emphasis on real‑time data and iterative design, HTE accelerates:
– Catalyst / ligand / base screening
– Broad design‑space exploration
– Early identification of scalable asymmetric routes
– Data-driven decision making
We combine digital tools, expert review, and structured manufacturability scoring to prioritise viable asymmetric routes before major lab investment. Routes are evaluated on:
– Technical feasibility
– Precedent at scale
– Robustness and complexity
– Cost and material availability
– Environmental and supply-chain considerations
Only the most robust routes progress to experimental development.
